Behind the breakthrough: Enabling the world’s first personalized CRISPR therapy

​In a landmark achievement for personalized medicine, researchers at the Children's Hospital of Philadelphia (CHOP) recently developed and delivered the world’s first personalized CRISPR therapy to a newborn diagnosed with a rare and life-threatening urea cycle disorder (UCD). The therapy, tailored to correct a unique mutation in the CPS1 gene, was identified, manufactured, and delivered within just six months. In this webinar, Sandy Ottensmann, VP/GM Gene Writing and Editing at Integrated DNA Technologies (IDT) will highlight the contributions of IDT and Aldevron, two Danaher operating companies whose scientific manufacturing expertise played a pivotal role in bringing this therapy to life.